We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Test Developed for Colorectal Cancer

By LabMedica International staff writers
Posted on 31 Oct 2012
Print article
A novel noninvasive test for colorectal cancer (CRC) screening demonstrated high sensitivity for detecting colorectal malignancy.

The test measures different kinds of DNA changes, known as methylation and mutation, along with a measure of fecal blood and by combining these measures, doctors can be shown the kinds of biological changes that are most frequently found in precancers and cancers in the colon.

Scientists at the Exact Sciences Corporation (Madison, WI, USA) working with those at the Mayo Clinic, (Rochester, MN, USA) analyzed 1,003 patient samples from 36 study sites. They developed an analytic algorithm for the novel, automated stool DNA-based test platform, which generated a positive or negative result for each patient. The specimens were collected either before colonoscopy bowel preparation in screening and surveillance patients or at least seven days postcolonoscopy from patients with colorectal cancer and large precancerous growths.

The control group included 796 patients with negative colonoscopies or small polyps of less than 1 cm, and the case group included 207 patients with confirmed CRC or precancers. The team was able to demonstrate that CRC and advanced precancers can be detected noninvasively by a manual multitarget stool DNA-based test (sDNA-MT) comprising exfoliated DNA markers plus β-actin and fecal hemoglobin. The clinical performance of the sDNA-MT test, using an optimized automated analytic platform and logistic algorithm could facilitate the routine performance of sDNA-MT for CRC screening by molecular diagnostics capable clinical laboratories.

Automated methylation, mutation and actin assays were performed with a Hamilton STARlet fluid handler (Hamilton Robotics; Reno, NV, USA), and Quantitative Allele-specific Real-time Target and Signal amplification (QuARTS) run on an ABI 7500 FastDx real time thermal cycler (Applied Biosystems; Foster City, CA, USA). The test detected 98% of all cancers as well as 83% of precursors with high-grade dysplasia, and 57% of precursors 1 cm or larger overall, at 90% nominal specificity. CRC patients were typically referred to colonoscopy for symptoms and test sensitivity may be elevated relative to that seen with screening.

Graham P. Lidgard, PhD, the chief science officer at Exact Sciences, said, "We are encouraged by the results of this study for detecting cancer and cancer precursors, especially the precursor lesions with high-grade dysplasia, an abnormality broadly recognized as being associated with a higher risk for progression to cancer itself. Current screening tests using only fecal occult blood are biologically limited in their ability to detect precursors to colorectal cancer." The study was presented at the 11th Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, held October 16-19, 2012, in Anaheim (CA, USA).

Related Links:

Exact Sciences Corporation
Mayo Clinic
Hamilton Robotics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.